Sandra González-Lana, 1 Beatriz Sanz, 1 Lara Pancorbo, 1 Claudia Olaizola, 1 María Sainz, 1Inês Pereira, Luis Serrano, Rosa Monge 1
1 Beonchip S.L. Zaragoza, Spain.
rmonge@beonchip.com
Reproducing human physiology in vitro remains a major challenge in drug discovery, as the lack of predictive preclinical models often results in high attrition rates during clinical trials. Microfluidic organ-on-chip technologies offer promising alternatives by enabling dynamic and physiologically relevant culture conditions that more accurately reproduce the human microenvironment.
Here, we present Beonchip’s microfluidic in vitro platforms as versatile tools for the development of advanced endothelial, epithelial, and organotypic models. These devices integrate key physiological cues—including fluidic mechanical forces (shear stress), 3D hydrogel-based stiffness, and co-culture strategies—allowing the recreation of functional tissue-like units. The platforms provide precise control of microenvironmental parameters, compatibility with high-content imaging, and seamless integration into standard laboratory workflows, making them highly suitable for pharmacological and toxicological applications.
Beonchip technology enables robust assessment of drug absorption, distribution, metabolism, and toxicity, while reducing reliance on animal experimentation. Furthermore, its adaptability supports the advancement of personalized medicine approaches. Collectively, these features contribute to accelerating the identification of candidate compounds with greater translational relevance and improving the overall efficiency of the drug development pipeline.
